We have generated an ELISA kit to accurately detect UHp levels, which is potentially a reliable biomarker of DKD (Diabetes/Metabolism Research and Reviews)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts
The UKPDS‐OM2 consistently overpredicted the risk of mortality and MI in both cohorts during follow‐up. Period effects may partially explain the differences. Results indicate that transferability is not satisfactory for all outcomes, and new or adjusted risk equations may be needed before applying the model to the Italian or Dutch settings (Diabetes, Obesity and Metabolism)
Temporal Trends in Comorbidities and Cardiometabolic Risk Factors at the Time of Diagnosis of Type 2 Diabetes in UK
CMM and high ASCVD risk have been consistently increasing across all age groups and gender, particularly CMM in those <50 years. Our findings indicate that the ESC‐EASD recommendations need to change to consider the young‐onset people with T2DM as a high‐risk group as recommended in the Primary Care Diabetes Europe Position Statement (Diabetes, Obesity and Metabolism)
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes. Clinicians and policy makers should ensure that metabolic surgery is appropriately considered in the management of patients with obesity and type 2 diabetes (The Lancet)
Lack of awareness of liver organ damage in patients with type 2 diabetes
Despite increasing evidence of a frequent hepatic involvement associated with poor prognosis, awareness of suffering of advanced liver disease in patients with T2D is remarkably low, likely reflecting little recognition also among the team of health care professionals (Acta Diabetologica)
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction (Cardiovascular Diabetology)
What’s in a Name? Redefining Type 2 Diabetes Remission
This opinion piece explores existing definitions of diabetes remission and proposes a contemporary and comprehensive framework to help define this clinical state
Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
As strategy-driven, head-to-head RCTs comparing SGLT-2i, GLP-1RA, or DPP-4i with metformin (and their combination with metformin) while ensuring glycemic and weight equipoise are unlikely to become available in the future, sharing and analyzing individual-level data from already conducted RCT would help to inform the evidence for the best first-line treatment(s) in subjects with type 2 diabetes and confirm or refute our finding (Diabetes Care)
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
Stabilization of a single trait among insulin sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression (Diabetes Care)
Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes
These results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population (Frontiers in Endocrinology)
ABCD and ABHI Position on Insulin Pumps
ABCD and ABHI have released a joint position statement “Supporting Management of People with diabetes using Out-of-Warranty Pumps while Ensuring Appropriate Patient Choice”
A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial
Hyperglycaemia was reduced without increasing hypoglycaemia in adolescents and young adults with type 1 diabetes using the investigational advanced hybrid closed-loop system compared with the commercially available MiniMed 670G system (The Lancet)
National Diabetes Audit, Diabetes Prevention Programme (DPP), Quarterly Data Release, 1st January – 30th September 2020
The NHS Diabetes Prevention Programme (DPP) is a joint commitment from NHS England, Public Health England (PHE) and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia
Global Trials Summit
Please join us for a series of vibrant and thought-provoking presentations by leaders in these fields who will discuss the results of recent pivotal trials in these areas. Live online discussions focusing on implementation of novel efficacious therapies will challenge clinicians as to how to adapt their daily practice.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo (NEJM)
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
In patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes, with notable differences in benefits and harms (BMJ)
SGLT2 inhibitors in type 2 diabetic patients with renal function impairment slows the annual renal function decline, in a real clinical practice
SGLT2is administration slows the decline observed in the annual renal function in T2DM patients with eGFR of < 60 ml/min/1.73m2, in clinical practice (Journal of Diabetes Investigation)
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i (Cardiovascular Diabetology)
Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
In propensity score-matched cohorts, GLP-1 RAs demonstrated significant benefits for both glycemic control and weight management over additional OAD(s) or insulin, respectively, indicating that they may represent the optimal choice at these points in the treatment pathway (BMJ Open, Diabetes Research & Care)
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses
Younger, rather than older, age at diabetes diagnosis was associated with higher risk of mortality and vascular disease. Early and sustained interventions to delay type 2 diabetes onset and improve blood glucose levels and cardiovascular risk profiles of those already diagnosed are essential to reduce morbidity and mortality (Diabetologia)
- 1
- 2
- 3
- …
- 210
- Next Page »
Glycosmedia is also available as an App: